Sign In
Buy GBT
$68.49
+0 (+0%)
At Close: Jan 27, 2023
Nomura Keeps Their Buy Rating on Prothena (PRTA)
02:44pm, Thursday, 23'rd Apr 2020
Nomura analyst Christopher Marai maintained a Buy rating on Prothena (PRTA) yesterday and set a price target of $19.00. The company's shares closed last
Analysts' Top Healthcare Picks: Eagle Pharmaceuticals (EGRX), Biogen (BIIB)
02:41pm, Thursday, 23'rd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eagle Pharmaceuticals (EGRX) and Biogen (BIIB) with bullish
These 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys?
10:39am, Thursday, 23'rd Apr 2020
These companies just raised significant cash to advance promising drug pipelines.
Nomura Maintains Their Buy Rating on Syndax Pharmaceuticals (SNDX)
03:47pm, Wednesday, 22'nd Apr 2020
In a report issued on April 20, Christopher Marai from Nomura maintained a Buy rating on Syndax Pharmaceuticals (SNDX), with a price target of $16.00. The
What's The Best Biotech Stock to Buy for Treating Sickle Cell Disease?
10:24am, Wednesday, 22'nd Apr 2020
Targeted therapies for treating sickle cell disease are finally here after a 60-year wait.
Global Blood Therapeutics Inc (NASDAQ:GBT) Expected to Post Earnings of -$1.48 Per Share
10:06am, Wednesday, 22'nd Apr 2020
Brokerages predict that Global Blood Therapeutics Inc (NASDAQ:GBT) will report earnings of ($1.48) per share for the current quarter, Zacks reports. Eight analysts have issued estimates for Global Blo
Global Blood Therapeutics Inc (NASDAQ:GBT) Expected to Announce Quarterly Sales of $3.40 Million
06:52am, Tuesday, 21'st Apr 2020
Wall Street analysts expect Global Blood Therapeutics Inc (NASDAQ:GBT) to announce $3.40 million in sales for the current fiscal quarter, according to Zacks. Eight analysts have issued estimates for G
Global Blood Therapeutics: Key Catalysts Remain As The Search For Clinical Benefit Continues
06:05pm, Monday, 20'th Apr 2020
Global Blood Therapeutics provided a quarterly update recently. In it, novel sickle cell disease drug, Oxbryta, netted a mere $2M in revenue. On the clinical fr
Frontier Capital Management Co. LLC Lowers Stock Holdings in Global Blood Therapeutics Inc (NASDAQ:GBT)
09:40am, Monday, 20'th Apr 2020
Frontier Capital Management Co. LLC trimmed its stake in Global Blood Therapeutics Inc (NASDAQ:GBT) by 60.6% in the 1st quarter, according to the company in its most recent filing with the Securities
Analysts Have Conflicting Sentiments on These Healthcare Companies: Danaher (DHR), Theratechnologies (THTX) and Galapagos (GLPG)
05:38pm, Thursday, 16'th Apr 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Danaher (DHR), Theratechnologies (THTX) and Galapagos (GLPG). Danaher
Unity Biotechnology (UBX) Gets a Buy Rating from Morgan Stanley
03:43pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Unity Biotechnology (UBX) today and set a price target of $13.00. The company's shares
Unity Biotechnology (UBX) Gets a Buy Rating from Morgan Stanley
03:43pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Unity Biotechnology (UBX – Research Report) today and set a
Morgan Stanley Reaffirms Their Hold Rating on Immunomedics (IMMU)
03:42pm, Wednesday, 15'th Apr 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Immunomedics (IMMU), with a price target of $22.00. The
Morgan Stanley Reaffirms Their Hold Rating on Immunomedics (IMMU)
03:42pm, Wednesday, 15'th Apr 2020
In a report released today,
Matthew Harrison
from Morgan Stanley maintained a
Hold
rating on Immunomedics (
IMMU
–
Research Report
), with a price target of
$22.00
. The company’s shares closed la
Denali Therapeutics (DNLI) Receives a Buy from Morgan Stanley
03:41pm, Wednesday, 15'th Apr 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Denali Therapeutics (DNLI), with a price target of $28.00. The
